Multiple myeloma · 13 regimens
Cost vs Efficacy · 7 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Carfilzomib and Panobinostat Variant #01 Partial | — | R 219 939 | 28d | — | — | — | — | — |
Carfilzomib and Dexamethasone (Kd) Variant #02 | — | R 139 752 | 28d | ~13.2 mo | ~45.7 mo | ~15 | ~R 2 096 286 PFS proxy · indirect | 8 |
Thalidomide and Dexamethasone (TD) Variant #12 | — | R 57 486 | 29d | ~18.6 mo | ~63.2 mo | ~20 | ~R 1 149 724 PFS proxy · indirect | 3 |
Ixazomib and Dexamethasone Variant #01 | — | R 33 178 | 28d | — | — | — | — | — |
Bortezomib and Pegylated liposomal doxorubicin Variant #01 | — | R 14 470 | 21d | — | — | — | — | — |
Lenalidomide and Dexamethasone (Rd) Variant #09 | — | R 14 094 | 35d | ~21.0 mo | ~55.4 mo | ~19 | ~R 267 783 PFS proxy · indirect | 26 |
Bortezomib and Dexamethasone (Vd) Variant #01 | — | R 8 080 | 28d | ~9.4 mo | ~38.7 mo | ~11 | ~R 88 876 PFS proxy · indirect | 10 |
Bortezomib and Vorinostat Variant #01 Partial | — | R 4 270 | 21d | ~7.6 mo | — | ~12 | ~R 51 237 PFS proxy · indirect | 1 |
Cyclophosphamide and Dexamethasone Variant #01 | — | R 384 | 28d | — | ~10.0 mo | — | — | 1 |
Selinexor and Dexamethasone (Sd) Variant #01 Partial | — | R 347 | 28d | — | — | — | — | — |
Melphalan flufenamide and Dexamethasone Variant #01 Partial | — | R 347 | 28d | ~6.8 mo | — | ~8 | ~R 2 778 PFS proxy · indirect | 1 |
Cyclophosphamide and Prednisone N/A - intrathecal component | — | R 93 | — | — | ~10.0 mo | — | — | 1 |
Pomalidomide and Dexamethasone (Pd) N/A - secondary systemic drug | — | R 0 | 28d | ~6.5 mo | ~17.4 mo | ~8 | ~R 0 PFS proxy · indirect | 13 |
13 of 13 regimens shown